NCT06524882

Brief Summary

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
252

participants targeted

Target at P50-P75 for phase_3

Timeline
18mo left

Started Oct 2024

Typical duration for phase_3

Geographic Reach
1 country

58 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Oct 2024Nov 2027

First Submitted

Initial submission to the registry

July 23, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 29, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

October 22, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2027

Last Updated

February 11, 2026

Status Verified

February 1, 2026

Enrollment Period

2.7 years

First QC Date

July 23, 2024

Last Update Submit

February 9, 2026

Conditions

Keywords

DichopticLuminopiaVivid VisionGamemovieglasses

Outcome Measures

Primary Outcomes (1)

  • Change in amblyopic eye logMAR distance VA

    between randomization and 18 weeks

    18 Weeks

Secondary Outcomes (1)

  • Functional Vision, Social, and Frustration/Worry quality of life domains as measured by the Pediatric Eye Questionnaire (PedEyeQ).

    18 Weeks

Study Arms (3)

Luminopia Group

EXPERIMENTAL

dichoptic movies/shows wearing the Luminopia headset prescribed 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day) 6 days a week with current optical correction if needed

Device: Luminopia

Vivid Vision Group

EXPERIMENTAL

dichoptic games using the Vivid Vision headset, prescribed approximately 25 minutes per day (treatment time to complete the day's sessions can be split into shorter sessions totaling about 25 minutes each day) 6 days per week with current optical correction if needed

Device: Vivid Vision

Continued Optical Correction Group

ACTIVE COMPARATOR

continued full-time optical correction alone if needed

Device: Optical Correction

Interventions

LuminopiaDEVICE

dichoptic movies/shows shown through a virtual reality headset

Luminopia Group

Glasses prescribed at investigator discretion

Continued Optical Correction Group

dichoptic video games played through a virtual reality headset

Vivid Vision Group

Eligibility Criteria

Age8 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age 8 to \<13 years.
  • VA, measured in each eye without cycloplegia in current refractive correction (if applicable) using the E-ETDRS VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
  • VA in the amblyopic eye 20/40 to 20/200 inclusive (33 to 72 letters with E-ETDRS).
  • VA in the fellow eye 20/25 or better (≥ 78 letters with E-ETDRS).
  • Interocular difference ≥ 3 logMAR lines (≥ 15 letters) i.e., amblyopic eye VA at least 3 logMAR lines worse than fellow eye VA).
  • Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
  • Criteria for strabismic amblyopia: At least one of the following must be met:
  • Presence of a heterotropia on examination at distance or near fixation (with optical correction), must be \<=5 prism diopters (∆) by SPCT at distance and near fixation.
  • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia).
  • Criteria for anisometropia: At least one of the following criteria must be met:
  • ≥1.00 D difference between eyes in spherical equivalent (SE).
  • ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • Criteria for combined-mechanism: Both of the following criteria must be met:
  • A criterion for strabismus is met (see above).
  • ≥1.00 D difference between eyes in SE OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
  • +29 more criteria

You may not qualify if:

  • Heterotropia more than 5∆ at distance or near (measured by SPCT in current correction)
  • Prism greater than a total of 8 diopters horizontal and 1 diopter vertical in the refractive correction at time of enrollment.
  • Current bifocal spectacles (eligible only if bifocal discontinued 2 weeks prior to enrollment).
  • Myopia greater than -6.00D spherical equivalent in either eye.
  • Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above visual acuity criteria are met using patch occlusion. Fogging is not permitted).
  • Diplopia more than once per week over the last week prior to enrollment by parental report.
  • History of light-induced seizures.
  • Known simulator sickness.
  • Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities are not excluded.
  • Immediate family member (biological or legal guardian, child, sibling, parent) of investigative site personnel directly affiliated with this study or an employee of the JAEB center for Health Research.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (58)

UAB Pediatric Eye Care; Birmingham Health Care

Birmingham, Alabama, 35294, United States

RECRUITING

Midwestern University Eye Institute

Glendale, Arizona, 85308, United States

RECRUITING

Phoenix Children's Medical Group - Ophthalmology

Scottsdale, Arizona, 85255, United States

RECRUITING

University of Arizona

Tucson, Arizona, 85711, United States

RECRUITING

Arkansas Childrens

Little Rock, Arkansas, 72202, United States

RECRUITING

McFarland Eye Care Center

Little Rock, Arkansas, 72205, United States

RECRUITING

University Eye Center at Ketchum Health

Anaheim, California, 92807, United States

RECRUITING

Univ. of California- Berkeley

Berkeley, California, 94720, United States

RECRUITING

Univ of California, Irvine- Gavin Herbert Eye Institute

Irvine, California, 92697, United States

RECRUITING

Stanford University

Palo Alto, California, 94303, United States

RECRUITING

Western University College of Optometry

Pomona, California, 91766, United States

RECRUITING

University of California, Davis

Sacramento, California, 95817, United States

RECRUITING

University of California San Francisco Department of Ophthalmology

San Francisco, California, 94143, United States

RECRUITING

Nova Southeastern University College of Optometry, The Eye Institute

Fort Lauderdale, Florida, 33382, United States

RECRUITING

University of South Florida (USF) Eye

Tampa, Florida, 33620, United States

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

RECRUITING

Illinois College of Optometry

Chicago, Illinois, 60616, United States

RECRUITING

Midwestern University Eye Institute

Downers Grove, Illinois, 60515, United States

RECRUITING

Progressive Eye Care

Lisle, Illinois, 60532, United States

RECRUITING

Indiana School of Optometry

Bloomington, Indiana, 47405, United States

RECRUITING

University of Iowa

Iowa City, Iowa, 52242, United States

RECRUITING

University of Kansas Dept of Ophthalmology

Prairie Village, Kansas, 66208, United States

RECRUITING

Greater Baltimore Medical Center

Baltimore, Maryland, 21204-5809, United States

RECRUITING

Wilmer Eye Institute

Baltimore, Maryland, 21287-9028, United States

RECRUITING

New England College of Optometry

Boston, Massachusetts, 02115, United States

RECRUITING

Boston Medical Center

Boston, Massachusetts, 02118, United States

RECRUITING

Boston Children's Hospital Waltham

Boston, Massachusetts, 02453, United States

RECRUITING

Michigan College of Optometry at Ferris State Univ

Big Rapids, Michigan, 49307, United States

RECRUITING

Pediatric Ophthalmology, P.C.

Grand Rapids, Michigan, 49546, United States

RECRUITING

Zenith Vision Development Center

Duluth, Minnesota, 55811, United States

RECRUITING

University of Minnesota-Minnesota Lions Children's Eye Clinic

Minneapolis, Minnesota, 55454, United States

RECRUITING

Mayo Clinic Department of Ophthalmology

Rochester, Minnesota, 55905, United States

RECRUITING

PineCone Vision Center

Sartell, Minnesota, 56377, United States

RECRUITING

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108, United States

RECRUITING

University of Nebraska Medical Center

Omaha, Nebraska, 68114, United States

RECRUITING

NYU Langone Health

New York, New York, 10017, United States

RECRUITING

State University of New York, College of Optometry

New York, New York, 10036, United States

RECRUITING

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

RECRUITING

Duke University Eye Center

Durham, North Carolina, 27710, United States

RECRUITING

University of North Dakota

Grand Forks, North Dakota, 58202, United States

RECRUITING

Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States

RECRUITING

Cole Eye Institute

Cleveland, Ohio, 44195, United States

RECRUITING

Ohio State University College of Optometry

Columbus, Ohio, 43210-1280, United States

RECRUITING

Rainbow Babies and Children's Hospital Dept of Ophth

Mayfield Heights, Ohio, 44124, United States

RECRUITING

River View Family Eyecare

Albany, Oregon, 97321, United States

RECRUITING

OHSU Casey Eye Institute

Portland, Oregon, 97239, United States

RECRUITING

Pediatric Ophthalmology of Erie

Erie, Pennsylvania, 16501, United States

RECRUITING

Conestoga Eye

Lancaster, Pennsylvania, 17601, United States

RECRUITING

Wills Eye Hospital

Philadelphia, Pennsylvania, 19107, United States

RECRUITING

Salus University/Pennsylvania College of Optometry

Philadelphia, Pennsylvania, 19141, United States

RECRUITING

Storm Eye Institute

Mt. Pleasant, South Carolina, 29464, United States

RECRUITING

Southern College of Optometry

Memphis, Tennessee, 38104, United States

RECRUITING

Baylor College of Medicine

Houston, Texas, 77030, United States

RECRUITING

University of Houston - College of Optometry

Houston, Texas, 77204, United States

RECRUITING

University of Houston College of Optometry

Houston, Texas, 77204, United States

RECRUITING

San Antonio Eye Center

San Antonio, Texas, 78215, United States

RECRUITING

Virginia Pediatric Eye Center

Norfolk, Virginia, 23502, United States

RECRUITING

Spokane Eye Clinical Research

Spokane, Washington, 99204, United States

RECRUITING

MeSH Terms

Conditions

Amblyopia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesVision DisordersSensation DisordersNeurologic ManifestationsEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Marjean T Kulp, OD

    Ohio State University

    STUDY CHAIR
  • Benajmin G Jastrzembski, MD

    University of California, Davis

    STUDY CHAIR

Central Study Contacts

Raymond T Kraker, MSPH

CONTACT

Brooke P Fimbel

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2024

First Posted

July 29, 2024

Study Start

October 22, 2024

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

November 1, 2027

Last Updated

February 11, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be made available after publication.
Access Criteria
Users accessing the data must enter an email address
More information

Locations